Ribose-Modified mRNA Cap Analogs for Stability and Translation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing cap structures in mRNA are inefficient in terms of stability and translation efficiency, leading to challenges in mRNA quality control and innate immunity.

Innovation Solution

Development of ribose-modified cap analogs with specific structural modifications, including variations in X1, X2, X3, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, and R15, which enhance in vitro transcription yield, capping rate, and translation efficiency.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If natural cap structure or existing cap analogs are used, then mRNA can be formed with basic translation initiation, but mRNA stability is insufficient and translation efficiency is limited

Engineering Contradiction:

ImprovemRNA stabilityVSAvoidtranslation efficiency

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent applies parameter changes by modifying the chemical structure of the cap analog at multiple positions (X1, X2, X3, R1-R15) to optimize both stability and translation efficiency. Specific modifications include changing the ribose modification type, adjusting methyl group positions, and modifying the guanine ring structure to achieve superior performance compared to natural caps

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates composite cap analog structures combining multiple functional elements: modified ribose sugars with various substituents, methylated guanine residues, and specific phosphodiester linkages. This composite approach allows simultaneous optimization of structural stability and translational function

Inventive Principle:

Principle #40Composite materials

2Productivity

If existing cap analogs are used to improve mRNA stability, then transcription yield increases, but decapping rate remains high and protein expression duration is limited

Engineering Contradiction:

Improvetranscription yieldVSAvoidprotein expression duration

Core Design Contradiction:

ProductivityVSDuration of action of stationary object

Solution Approach 1:

The patent applies preliminary anti-action by incorporating structural features into the cap analog that preemptively resist decapping enzymes. The modified ribose structures and methyl group configurations are designed to block access to the 5' end by exonucleases and decapping proteins, thereby extending mRNA half-life and protein expression duration

Inventive Principle:

Principle #9Preliminary anti-action

3Productivity

If cap structure modifications are made to enhance translation efficiency, then ribosome recognition improves, but structural complexity increases

Engineering Contradiction:

Improvetranslation efficiencyVSAvoidcap analog structure complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent applies local quality by making specific targeted modifications at critical positions in the cap structure (such as the 2'-OH group of the first ribose, the N7 methyl group of guanine) while maintaining simplicity in other regions. This localized optimization approach enhances ribosome recognition without unnecessarily complicating the entire molecular structure

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS12576099B2Ribose-modified cap analog and use thereof

Publication Date: 2026.03.17 BEIJING YUEKANGKECHUANG PHARM TECH CO LTD

AI summary

The present disclosure provides a ribose-modified cap analog and a use thereof, and belongs to the technical field of chemical and biological engineering. The ribose-modified cap analog has a structure of formula (I). The ribose-modified cap analog described herein can improve the stability of mRNA and/or the translation efficiency of mRNA.